Annual Reporting Under an Open Investigational New Drug Application: Regulatory Operations and eCTD Submission Considerations for a KRAS-Targeted Combination Therapy in Metastatic Pancreatic Adenocarcinoma

The annual report required under 21 C.F.R. 312.33 is a short document with a long list of contributors: clinical operations, pharmacovigilance, nonclinical development, chemistry, manufacturing, and controls, quality, and regulatory publishing all supply content that must reconcile to the same data cutoff. This article prepares the regulatory operations components of the first annual report for a hypothetical open IND in which an oral KRAS-pathway inhibitor is combined with a standard multi-agent chemotherapy backbone as first-line treatment of metastatic pancreatic adenocarcinoma. It sets out the reporting period and deadline, study accounting (56 of 80 planned participants entered), the content required by each paragraph of the regulation, placement of every component in Module 1.13 of the eCTD, Form FDA 1571 entries, a draft cover letter, and an 11-step timeline. It corrects a common error, placement of the report in Module 1.3, and closes with recommendations for regulatory operations teams.Keywords: IND annual report; 21 C.F.R. 312.33; eCTD Module 1.13; regulatory operations; Form FDA 1571; submission lifecycle

Authors

Institutions

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-11-19
DOI
https://doi.org/10.5281/zenodo.24373167
Primary Topic
Healthcare Regulation
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Annual Reporting Under an Open Investigational New Drug Application: Regulatory Operations and eCTD Submission Considerations for a KRAS-Targeted Combination Therapy in Metastatic Pancreatic Adenocarcinoma

Avinash Dundigalla, Peivand Pirouzi, Afeefa Mahmood, Kritica
Zenodo (CERN European Organization for Nuclear Research)
Healthcare Regulation
article

Annual Reporting Under an Open Investigational New Drug Application: Regulatory Operations and eCTD Submission Considerations for a KRAS-Targeted Combination Therapy in Metastatic Pancreatic Adenocarcinoma

Avinash Dundigalla, Peivand Pirouzi, Afeefa Mahmood, Kritica
article en

Abstract

The annual report required under 21 C.F.R. 312.33 is a short document with a long list of contributors: clinical operations, pharmacovigilance, nonclinical development, chemistry, manufacturing, and controls, quality, and regulatory publishing all supply content that must reconcile to the same data cutoff. This article prepares the regulatory operations components of the first annual report for a hypothetical open IND in which an oral KRAS-pathway inhibitor is combined with a standard multi-agent chemotherapy backbone as first-line treatment of metastatic pancreatic adenocarcinoma. It sets out the reporting period and deadline, study accounting (56 of 80 planned participants entered), the content required by each paragraph of the regulation, placement of every component in Module 1.13 of the eCTD, Form FDA 1571 entries, a draft cover letter, and an 11-step timeline. It corrects a common error, placement of the report in Module 1.3, and closes with recommendations for regulatory operations teams.Keywords: IND annual report; 21 C.F.R. 312.33; eCTD Module 1.13; regulatory operations; Form FDA 1571; submission lifecycle

Zenodo (CERN European Organization for Nuclear Research)
Northeastern University (US)
Healthcare Regulation
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon